Pressmeddelande -
We welcome Aino Råberg as Drug Substance Lead Manufacturing at Scandinavian Biopharma
Scandinavian Biopharma continues to grow and welcome new colleagues. We are now further strengthening our organisation in manufacturing and are pleased to welcome Aino Råberg as our Drug Substance Lead.
Aino has extensive experience from production in the pharmaceutical and life science industry and most recently came from a consulting position where she had various assignments at Octapharma, SOBI and Novavax. Aino led projects in both cultivation and purification, and worked with qualifications, process development and process validations.
- Joining a company that has a vaccine candidate in the late clinical phase feels very exciting. Here I can really use all my previous experiences within this field. To also be able to contribute to a project that can make a real difference feels great. This team is passionate about developing an ETEC vaccine for the whole world, says Aino Råberg.
- Manufacturing of biological drugs is a unique and complex process and having Aino join the team is very important to us. We highly value her previous experience with recombinant proteins, both from commercial production and vaccine production in the development stage, says Björn Sjöstrand, CEO Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
